AEON Biopharma, Inc.

AEON Biopharma, Inc. (Nasdaq: AEON) is a clinical-stage biopharmaceutical company focused on botulinum toxin therapeutic candidates, which completed its de-SPAC transaction with Priveterra Acquisition Corp, a blank-check vehicle sponsored by Priveterra Sponsor, LLC that conducted its initial public offering in 2021. The company operates in the biotechnology and specialty therapeutics sector. The April 2023 Form 10-K/A filing, bearing accession number 0001104659-23-043628, represents an amendment to the company's annual report on record with the SEC as AEON Biopharma, Inc. following the completion of its merger. For comprehensive filing history, sponsor details, and real-time SPAC analytics on AEON and hundreds of other transactions, sign up for full data access at SpacDesk.